Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNA(Lys3) are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells

被引:10
作者
ElDiraniDiab, R
SarihCottin, L
Delord, B
Dumon, B
Moreau, S
Toulme, JJ
Fleury, H
Litvak, S
机构
[1] CNRS, IBGC, F-33077 BORDEAUX, FRANCE
[2] INST FEDERAT RECH PATHOL INFECT, IFR 66, F-33077 BORDEAUX, FRANCE
[3] UNIV BORDEAUX 2, INSERM U386, F-33076 BORDEAUX, FRANCE
[4] UNIV BORDEAUX 2, VIROL LAB, F-33076 BORDEAUX, FRANCE
关键词
D O I
10.1128/AAC.41.10.2141
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Retroviral reverse transcriptase (RT) is involved in the selection of a specific tRNA primer which initiates proviral DNA minus-strand synthesis. Studies of the interactions between human immunodeficiency virus type I (HIV-1) RT and primer tRNA(Lys3) have shown that the dihydrouridine (diHU), anticodon, and pseudouridine regions of tRNA are highly protected in the RT-tRNA complex The CCA 3' end of tRNA is also in close contact with the enzyme during the cDNA initiation step. Using synthetic oligoribonucleotides corresponding to the anticodon and diHU regions, we have previously shown a low but significant inhibition of HIV-1 RT activity (37). We extend this observation and show that primer tRNA-derived oligodeoxynucleotides (ODNs) carrying a phosphorothioate (PS) modification are strong inhibitors of HIV-1 RT. The affinity of PS-ODNs for the enzyme was monitored by gel mobility shift electrophoresis. Experiments with HIV-l-infected human cells (MT-2 cells) were performed with the latter ODNs. A PS-ODN corresponding to the 3' end of tRNA(Lys3) (acceptor stem [AS]) was able to inhibit HIV-1 replication. No effect of the other modified ODNs was observed in infected cells. The analysis of HIV-1 RNase H activity in a cell-free system strongly suggests that the inhibitory effect of the PS-AS may be mediated via both a sense and an antisense mechanism.
引用
收藏
页码:2141 / 2148
页数:8
相关论文
共 46 条
  • [1] AGRAWAL S, 1991, PROSPECTS ANTISENSE, P143
  • [2] Agrawal S., 1994, J BIOTECH HEALTHCARE, V1, P167
  • [3] GENETIC-VARIABILITY OF THE AIDS VIRUS - NUCLEOTIDE-SEQUENCE ANALYSIS OF 2 ISOLATES FROM AFRICAN PATIENTS
    ALIZON, M
    WAINHOBSON, S
    MONTAGNIER, L
    SONIGO, P
    [J]. CELL, 1986, 46 (01) : 63 - 74
  • [4] ANDREOLA ML, 1992, J BIOL CHEM, V267, P19356
  • [5] APOSHIAN HV, 1962, J BIOL CHEM, V237, P519
  • [6] HIV-1 reverse transcriptase shows no specificity for the binding of primer tRNA(LyS3)
    Arion, D
    Harada, R
    Li, XG
    Wainberg, MA
    Parniak, MA
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 225 (03) : 839 - 843
  • [7] Arts EJ, 1996, ADV VIRUS RES, V46, P97, DOI 10.1016/S0065-3527(08)60071-8
  • [8] ANTIVIRAL ACTIVITY OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE COMPLEMENTARY TO HUMAN CYTOMEGALOVIRUS RNA WHEN USED IN COMBINATION WITH ANTIVIRAL NUCLEOSIDE ANALOGS
    AZAD, RF
    BROWNDRIVER, V
    BUCKHEIT, RW
    ANDERSON, KP
    [J]. ANTIVIRAL RESEARCH, 1995, 28 (02) : 101 - 111
  • [9] ANALYSIS OF THE INTERACTIONS OF HIV-1 REPLICATION PRIMER TRANSFER RNA(LYS,3) WITH NUCLEOCAPSID PROTEIN AND REVERSE-TRANSCRIPTASE
    BARAT, C
    SCHATZ, O
    LEGRICE, S
    DARLIX, JL
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1993, 231 (02) : 185 - 190
  • [10] HIV-1 REVERSE-TRANSCRIPTASE SPECIFICALLY INTERACTS WITH THE ANTICODON DOMAIN OF ITS COGNATE PRIMER TRANSFER-RNA
    BARAT, C
    LULLIEN, V
    SCHATZ, O
    KEITH, G
    NUGEYRE, MT
    GRUNINGERLEITCH, F
    BARRESINOUSSI, F
    LEGRICE, SFJ
    DARLIX, JL
    [J]. EMBO JOURNAL, 1989, 8 (11) : 3279 - 3285